Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890275736> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W2890275736 abstract "e15607 Background: Preclinical studies have shown synergy between everolimus, an mTOR inhibitor, radiation and platinum agents in EC. We conducted a multi-institutional phase IB trial to determine the recommended phase II dose (RP2D) of concurrent everolimus with carboplatin and radiation in non-metastatic EC pts. Methods: Patients with untreated, localized EC and ECOG performance status 0-1 were eligible. Following two cycles of induction Capecitabine/Oxaliplatin (XELOX), pts without evidence of disease progression, received concurrent chemoradiation (total dose: 50.4Gy in 28 fractions), weekly carboplatin (AUC = 2), and escalating doses of everolimus. A standard 3+3 dose escalation design was used. Results: Nineteen patients were enrolled. There were two screen failures (thrombocytopenia, metastases) and 4 pts were removed due to poor tolerance of XELOX (2 pts) or disease progression (2 pts). A total of 13 pts with stage II/III (6/7) EC completed concurrent therapy. Median age 58 (44-71yrs), 85% males; all had adenocarcinoma deemed resectable. One pt at dose level 1 (2.5 mg/QOD), was replaced due to ongoing anxiety. One of 6 pts had a DLT (bowel ischemia). At dose level 2 (2.5mg/QD), 2 out of 6 patients had a DLT (fever with neutropenia and nausea). The RP2D of everolimus was 2.5 mg QOD. Clinically relevant ≥ grade 3 toxicities included lymphopenia (25%), dehydration (12%), fatigue, leukopenia, hyponatremia, abdominal pain, vomiting (each 6%). R0 resection was achieved in 100%; a pathologic response rate (RR) of 40% and a pathologic complete response (pCR) rate of 23% were observed. The 2-year PFS and OS were 50% and 49.6% respectively. Conclusions: The RP2D of everolimus with concurrent weekly carboplatin and radiation is 2.5 mg QOD. Despite the 100% R0 resection rate, the pCR and OS rates were within the expected historical controls. (The study was funded by Novartis Pharmaceuticals) Clinical trial information: NCT01490749." @default.
- W2890275736 created "2018-09-27" @default.
- W2890275736 creator A5010399375 @default.
- W2890275736 creator A5010469485 @default.
- W2890275736 creator A5014218695 @default.
- W2890275736 creator A5015060656 @default.
- W2890275736 creator A5025524746 @default.
- W2890275736 creator A5036672833 @default.
- W2890275736 creator A5042210553 @default.
- W2890275736 creator A5043235685 @default.
- W2890275736 creator A5043993232 @default.
- W2890275736 creator A5045720980 @default.
- W2890275736 creator A5046360681 @default.
- W2890275736 creator A5052955777 @default.
- W2890275736 creator A5053851809 @default.
- W2890275736 creator A5057176768 @default.
- W2890275736 creator A5065088834 @default.
- W2890275736 creator A5067698084 @default.
- W2890275736 creator A5074298815 @default.
- W2890275736 creator A5080256711 @default.
- W2890275736 creator A5082875185 @default.
- W2890275736 creator A5088178599 @default.
- W2890275736 date "2017-05-20" @default.
- W2890275736 modified "2023-09-24" @default.
- W2890275736 title "Phase IB study of induction chemotherapy with XELOX, followed by radiation therapy, carboplatin, and everolimus in patients with locally advanced esophageal cancer (EC)." @default.
- W2890275736 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e15607" @default.
- W2890275736 hasPublicationYear "2017" @default.
- W2890275736 type Work @default.
- W2890275736 sameAs 2890275736 @default.
- W2890275736 citedByCount "0" @default.
- W2890275736 crossrefType "journal-article" @default.
- W2890275736 hasAuthorship W2890275736A5010399375 @default.
- W2890275736 hasAuthorship W2890275736A5010469485 @default.
- W2890275736 hasAuthorship W2890275736A5014218695 @default.
- W2890275736 hasAuthorship W2890275736A5015060656 @default.
- W2890275736 hasAuthorship W2890275736A5025524746 @default.
- W2890275736 hasAuthorship W2890275736A5036672833 @default.
- W2890275736 hasAuthorship W2890275736A5042210553 @default.
- W2890275736 hasAuthorship W2890275736A5043235685 @default.
- W2890275736 hasAuthorship W2890275736A5043993232 @default.
- W2890275736 hasAuthorship W2890275736A5045720980 @default.
- W2890275736 hasAuthorship W2890275736A5046360681 @default.
- W2890275736 hasAuthorship W2890275736A5052955777 @default.
- W2890275736 hasAuthorship W2890275736A5053851809 @default.
- W2890275736 hasAuthorship W2890275736A5057176768 @default.
- W2890275736 hasAuthorship W2890275736A5065088834 @default.
- W2890275736 hasAuthorship W2890275736A5067698084 @default.
- W2890275736 hasAuthorship W2890275736A5074298815 @default.
- W2890275736 hasAuthorship W2890275736A5080256711 @default.
- W2890275736 hasAuthorship W2890275736A5082875185 @default.
- W2890275736 hasAuthorship W2890275736A5088178599 @default.
- W2890275736 hasConcept C121608353 @default.
- W2890275736 hasConcept C126322002 @default.
- W2890275736 hasConcept C143998085 @default.
- W2890275736 hasConcept C2776611710 @default.
- W2890275736 hasConcept C2776694085 @default.
- W2890275736 hasConcept C2778239845 @default.
- W2890275736 hasConcept C2779699572 @default.
- W2890275736 hasConcept C2779742542 @default.
- W2890275736 hasConcept C2781451048 @default.
- W2890275736 hasConcept C509974204 @default.
- W2890275736 hasConcept C71924100 @default.
- W2890275736 hasConceptScore W2890275736C121608353 @default.
- W2890275736 hasConceptScore W2890275736C126322002 @default.
- W2890275736 hasConceptScore W2890275736C143998085 @default.
- W2890275736 hasConceptScore W2890275736C2776611710 @default.
- W2890275736 hasConceptScore W2890275736C2776694085 @default.
- W2890275736 hasConceptScore W2890275736C2778239845 @default.
- W2890275736 hasConceptScore W2890275736C2779699572 @default.
- W2890275736 hasConceptScore W2890275736C2779742542 @default.
- W2890275736 hasConceptScore W2890275736C2781451048 @default.
- W2890275736 hasConceptScore W2890275736C509974204 @default.
- W2890275736 hasConceptScore W2890275736C71924100 @default.
- W2890275736 hasLocation W28902757361 @default.
- W2890275736 hasOpenAccess W2890275736 @default.
- W2890275736 hasPrimaryLocation W28902757361 @default.
- W2890275736 isParatext "false" @default.
- W2890275736 isRetracted "false" @default.
- W2890275736 magId "2890275736" @default.
- W2890275736 workType "article" @default.